logo
Share SHARE
FONT-SIZE Plus   Neg

GSK Submits Supplemental NDAs To FDA For Dabrafenib/trametinib Combination

U.K.-based drug maker GlaxoSmithKline plc (GSK, GSK.L) Tuesday announced submission of supplemental New Drug Applications or NDAs to the U.S. Food and Drug Administration or FDA for use of a BRAF inhibitor, dabrafenib, in combination with a MEK inhibitor trametinib. These applications are based from a randomised Phase I/II study comparing dabrafenib monotherapy to combination therapy with dabrafenib and trametinib in patients with BRAF V600E and V600K mutation positive metastatic melanoma.

The use of these drugs in combination is investigational, the company said, and is not approved anywhere else. European review of the MAA submission for trametinib, both as monotherapy and in combination with dabrafenib, is ongoing. CHMP has reverted from the accelerated assessment review process to standard timelines to allow sufficient time for review of the submission.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A new species of 'super-armored' worm, almost bizarre beyond description, has been discovered. Good thing this one's no longer around. Stocks moved sharply lower over the course of the trading day on Monday amid continued concerns about Greece and the possibility the debt-laden country will exit the eurozone. With the steep drop on the day, the Dow fell to its lowest closing level in almost five months. The most "American" vehicle isn't Built Ford Tough. It's not in jingles sung by John Mellencamp or Bob Seger, and it probably isn't kickin' up backroads dust somewhere in the Heartland.
comments powered by Disqus
Follow RTT